[WSJ] Will ‘Son of Sovaldi’ Cause State Medicaid Programs to Erect High Hurdles?

Oct 13, 2014

How might state Medicaid programs cope with a new and equally expensive hepatitis C treatment from Gilead Sciences GILD -4.20%? A new report released just as the FDA late last week approved Harvoni, which will cost $94,500 for a 12-week regimen, may offer some insights, at least according to a trade group for the state programs.

Sovaldi, you may recall, costs $1,000 a pill, or $84,000, for a 12-week regimen and the price tag has become a flash point in the national debate over the rising cost of prescription medicines. State Medicaid programs and pharmacy benefit managers call the drug a budget buster.

[button title=”Read More” link=”http://blogs.wsj.com/pharmalot/2014/10/13/will-son-of-sovaldi-cause-state-medicaid-programs-to-erect-high-hurdles/” target=”_blank” size=”” color=”” class=””]